Differentiated thyroid cancer (DTC) is associated with an excellent disease-specific survival rate exceeding 95%. Nonetheless, lymph node metastases in the central and lateral neck regions are observed in 50–60% of patients, often identified only during surgical intervention. Following appropriate surgical management and, when indicated, adjuvant radioactive iodine (RAI) therapy, the likelihood of persistent or recurrent disease remains below 20% in low- and intermediate-risk cases. Distant metastases occur in less than 5% of patients, typically affecting the lungs and bones, and less commonly the brain. Most of these advanced cases are characterized by RAI-refractory disease, significantly limiting treatment options to palliative local therapies such as external beam radiation or selective surgical resection, which offer limited survival benefits. Recent advances in molecular profiling and the advent of targeted therapies have provided promising therapeutic avenues for patients with aggressive and treatment-resistant forms of DTC, highlighting the importance of precision medicine in improving disease-specific outcomes.